Browse the evidence

Tirzepatide demonstrated a positive impact on the cardiovascular system.

Tirzepatide may be beneficial for patients with cardiovascular concerns related to diabetes.

GLP-1 receptor agonists (GLP-1RA) significantly reduce major adverse cardiovascular events (MACE) with a pooled hazard ratio of 0.86.

GLP-1RA can be recommended for reducing cardiovascular risks in patients with type 2 diabetes and obesity.

Both systolic blood pressure (SBP) and weight reductions are independently associated with reduced MACE risk.

Weight management and blood pressure control should be emphasized in treatment plans for these patients.

The use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in obesity management is increasing.

Practitioners should be aware of the growing role of GLP-1 RAs in obesity treatment.

Endobariatrics (EBT) offers durable weight loss with low complication rates.

EBT can be considered a viable option for patients seeking weight loss with minimal risks.

The combination of an amylin analog and other anti-obesity peptide drugs has demonstrated higher clinical efficacy in reducing body weight than monotherapy.

Combination therapies may be more effective for weight loss than single-drug treatments.

Obesity is associated with many health risks, including hypertension, hyperlipidemia, T2D, CHD, stroke, gallbladder disease, osteoarthritis, sleep apnea, respiratory problems, and some cancers.

Healthcare practitioners should be aware of the extensive health risks associated with obesity.

Up to 40% of weight loss following treatment with GLP-1RA is accounted for by lean mass.

Clinicians should be aware of potential lean mass loss when prescribing GLP-1RA therapies.

Early change in eating-related self-regulation is a stronger predictor of longer-term change in eating-related self-efficacy than the reverse.

Focusing on enhancing self-regulation may be crucial for improving self-efficacy in obesity treatment.

52.9% of Semaglutide users reached the 2.4 mg dose compared to 77.6% of Tirzepatide users reaching 15 mg.

Practitioners should note the higher success rate of Tirzepatide in reaching the maintenance dose.

Non-optimized dosing was associated with higher estimated monthly plan costs.

Practitioners should consider the cost implications of dosing strategies.

Management of weight should be patient-centered and consider age, health conditions, medications, and reproductive potential.

Practitioners should tailor weight management strategies to individual patient needs and circumstances.

Key considerations when treating weight in women include the impact on sex-specific conditions and reproductive considerations of anti-obesity medications.

Practitioners should incorporate sex-specific and reproductive considerations into weight treatment plans.

Discontinuation of obesity medications often results in weight regain and reversal of health benefits.

Practitioners should monitor patients for weight regain after discontinuation and implement strategies to mitigate this.

Optimal obesity management requires a systematic assessment that extends beyond body mass index (BMI).

Clinicians should incorporate comprehensive assessments in obesity management.

Treatment modalities for obesity include lifestyle modification, pharmacotherapy, and bariatric surgery.

Clinicians should consider a range of treatment options for obesity management.

Various treatment modalities, including GLP-1 agonists and dual GLP-1/GIP agonists, are reviewed for their effects on hepatic steatosis and fibrosis.

Practitioners should consider these treatment modalities for managing MASLD.

Female sex independently predicted greater TBWL, while insulin use and higher T2D medication burden were associated with less TBWL.

Understanding these predictors can help tailor treatment strategies for weight loss.

Obesity is a significant pathogenic factor for multiple chronic conditions and ranks as the sixth leading risk factor for mortality and disability nationwide.

Healthcare practitioners should recognize obesity as a critical factor in managing chronic diseases.

GLP-1 receptor agonists and dual incretin agonists provide clinically significant benefits in weight reduction, blood pressure modulation, lipid profile improvement, and cardiovascular risk mitigation.

Practitioners can consider GLP-1 receptor agonists and dual agonists as effective options for managing weight and cardiovascular health in patients with T2DM and obesity.

Treatment would produce 75,800 quality-adjusted life-years valued at $7 billion.

Obesity treatment can significantly enhance life quality and longevity for Medicaid beneficiaries.

Dual agonists represent a transformative therapeutic class for metabolic disease management.

Clinicians should consider dual agonists as a key component in the management of metabolic diseases.

RYGB showed significantly greater weight loss than SG at both 12 months (30.3% vs. 25.4%; p < 0.001) and 24 months (26.3% vs. 21.4%; p < 0.001).

Practitioners should consider RYGB for patients seeking greater weight loss outcomes.

Both medications exhibited favorable cardiovascular profiles, though gastrointestinal adverse events constitute the predominant tolerability concern.

While both tirzepatide and retatrutide may improve cardiovascular health, practitioners should monitor for gastrointestinal side effects.